|Day Low/High||41.43 / 42.82|
|52 Wk Low/High||27.53 / 48.99|
- $545,000 awarded to help improve Duchenne muscular dystrophy diagnosis and screening across the globe -
- $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations -
Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing
Translarna™ Approved by Brazilian Health Regulatory Authority (ANVISA)
In trading on Tuesday, shares of PTC Therapeutics Inc crossed below their 200 day moving average of $37.12, changing hands as low as $37.01 per share. PTC Therapeutics Inc shares are currently trading off about 2.5% on the day.
- Ambulatory Duchenne patients who are 5 years and older with a nonsense mutation can now access a treatment that targets the underlying cause -
SOUTH PLAINFIELD, N.J.
WAYLIVRA, the first and only therapy for the treatment of familial chylomicronemia syndrome (FCS), has received a positive opinion from the CHMP
Investors in PTC Therapeutics Inc saw new options become available today, for the April 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new April 12th contracts and identified one put and one call contract of particular interest.
Investors in PTC Therapeutics Inc saw new options begin trading this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 218 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
- STRIVE Awards have Supported Over 20 Projects in 15 Countries-
Investors in PTC Therapeutics Inc saw new options become available today, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.
- $500,000 funding to improve Duchenne muscular dystrophy diagnosis and screening in 2019 -
- Multiple products to be launched by 2023 potentially generating ~$1.5 billion revenue annually-
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.